Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$2.01
+1.0%
$1.84
$1.21
$3.81
$49.64M0.68254,575 shs278,993 shs
enGene Holdings Inc. stock logo
ENGN
enGene
$3.68
-3.9%
$3.60
$2.65
$11.00
$195.73M-0.42126,648 shs75,216 shs
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$4.35
-1.6%
$3.85
$2.24
$28.93
$204.76M2.81813,735 shs186,194 shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$4.52
+1.8%
$4.48
$3.55
$16.11
$201.06M0.51296,041 shs98,392 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
+0.51%+6.99%+6.42%+20.61%+43.17%
enGene Holdings Inc. stock logo
ENGN
enGene
0.00%+2.41%+14.33%-4.25%-57.54%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
+4.74%+2.55%-7.72%+70.66%-80.52%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
+5.46%+4.23%-12.60%+2.07%-60.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.6889 of 5 stars
1.00.00.00.01.12.51.3
enGene Holdings Inc. stock logo
ENGN
enGene
2.8149 of 5 stars
3.53.00.00.01.52.50.6
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.1585 of 5 stars
3.32.00.00.01.71.70.6
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
3.1887 of 5 stars
4.41.00.00.02.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
2.00
Hold$1.67-17.08% Downside
enGene Holdings Inc. stock logo
ENGN
enGene
3.00
Buy$23.29532.76% Upside
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.60
Moderate Buy$29.56579.44% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.82
Moderate Buy$15.60245.13% Upside

Current Analyst Ratings Breakdown

Latest AADI, FDMT, YMAB, and ENGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/27/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
6/11/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
5/29/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.00
5/28/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00 ➝ $18.00
5/24/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/19/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
5/10/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $25.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$25.07M1.98N/AN/A$4.29 per share0.47
enGene Holdings Inc. stock logo
ENGN
enGene
N/AN/AN/AN/A$5.35 per shareN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$40K5,038.39N/AN/A$11.05 per share0.39
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$87.68M2.33N/AN/A$2.05 per share2.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)
enGene Holdings Inc. stock logo
ENGN
enGene
-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%N/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$160.87M-$3.18N/AN/AN/A-767,126.06%-33.26%-30.68%8/6/2025 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.64N/AN/AN/A-31.84%-30.59%-22.70%8/11/2025 (Estimated)

Latest AADI, FDMT, YMAB, and ENGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.6922N/AN/AN/A$0.52 millionN/A
6/10/2025Q2 2025
enGene Holdings Inc. stock logo
ENGN
enGene
-$0.4768-$0.51-$0.0332-$0.51N/AN/A
5/13/2025Q1 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million
5/8/2025Q1 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
enGene Holdings Inc. stock logo
ENGN
enGene
N/AN/AN/AN/AN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.89
4.54
enGene Holdings Inc. stock logo
ENGN
enGene
0.09
12.66
12.66
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
12.36
12.36
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.77
4.35

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
enGene Holdings Inc. stock logo
ENGN
enGene
64.16%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
37.30%
enGene Holdings Inc. stock logo
ENGN
enGene
10.40%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
9.60%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
4024.70 million15.49 millionOptionable
enGene Holdings Inc. stock logo
ENGN
enGene
3151.10 million45.79 millionN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
12046.33 million41.88 millionOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.28 million36.36 millionOptionable

Recent News About These Companies

YMAB Y-mAbs Therapeutics, Inc. - Seeking Alpha
Y mAbs Therapeutics News (YMAB) - Investing.com
Cantor Fitzgerald Comments on YMAB FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aadi Bioscience stock logo

Aadi Bioscience NASDAQ:AADI

$2.01 +0.02 (+1.01%)
As of 07/9/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

enGene stock logo

enGene NASDAQ:ENGN

$3.68 -0.15 (-3.92%)
Closing price 04:00 PM Eastern
Extended Trading
$3.70 +0.01 (+0.41%)
As of 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

4D Molecular Therapeutics stock logo

4D Molecular Therapeutics NASDAQ:FDMT

$4.35 -0.07 (-1.58%)
Closing price 04:00 PM Eastern
Extended Trading
$4.51 +0.16 (+3.68%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$4.52 +0.08 (+1.80%)
Closing price 04:00 PM Eastern
Extended Trading
$4.53 +0.01 (+0.11%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.